Brief: Portage Biotech Enters Agreement With U.S. National Cancer Institute And Stimunity
Brief: Portage Biotech Provides Update On Clinical-Stage, Development Programs
Brief: Portage Biotech Announces Results For Q3 Of 2022 Fiscal Year
Brief: Portage Biotech Reports Financial Results For Q2 2022
Brief: Portage Biotech Announces Results For First Quarter Of 2022 Fiscal Year
Brief: Portage Biotech Inc Highlights First Patient Dosed In IMP-MEL Study Of PORT-2
Brief: Portage Biotech Announces Results For Fiscal Year Ended March 31, 2021
Sale of Shares in Portage Biotech
Portage Biotech bottoms Nasdaq on discounted share offering